Form 4: Structure Therapeutics CFO Reports Share Vesting and Tax-Related Dispositions

Structure Therapeutics Inc.'s Chief Financial Officer, Jun Yoon, reported recent acquisitions of performance-vesting restricted share units and dispositions for tax obligations, alongside updates to direct and indirect shareholdings.

Summary

• Jun Yoon, Chief Financial Officer of Structure Therapeutics Inc., reported changes in his beneficial ownership of the company's Ordinary Shares and American Depositary Shares (ADSs).
• On March 1, 2025, 5,940 Ordinary Shares were disposed of at $7.9166 to satisfy income tax obligations associated with the vesting of a restricted share unit award.
• On July 1, 2025, 39,606 Ordinary Shares were acquired at $0 due to the vesting of performance-vesting restricted share units (PSUs), as certain performance criteria were met.
• Also on July 1, 2025, an additional 7,089 Ordinary Shares were disposed of at $6.8366 for income tax obligations related to vesting.
• Following these transactions, Jun Yoon directly holds 1,319,876 Ordinary Shares.
• Indirectly, 1,554,586 Ordinary Shares are held through The Yoon Family Trust, dated December 11, 2019.
• 831 American Depositary Shares (ADSs) were acquired on May 21, 2025, representing 2,963 Ordinary Shares, with 2,946 ADSs directly beneficially owned. Each ADS is convertible into three Ordinary Shares and has no expiration date.

Sentiment

Score: 7

Explanation: The filing indicates the vesting of performance-based equity awards, suggesting the achievement of internal targets, which is positive. The dispositions are routine tax withholdings, not open market sales, which is neutral. Overall, it reflects a positive internal milestone for the company's executive compensation program.

Positives

• Acquisition of 39,606 Ordinary Shares through the vesting of performance-vesting restricted share units (PSUs), indicating the achievement of certain performance criteria.
• Acquisition of 831 American Depositary Shares (ADSs) representing 2,963 Ordinary Shares.

Negatives

• Disposition of 5,940 Ordinary Shares at $7.9166 and 7,089 Ordinary Shares at $6.8366 to cover income tax obligations from vesting awards.

Future Outlook

The remaining 50% of the performance-vesting restricted share units (PSUs) are scheduled to vest on January 1, 2027, contingent on the reporting person's continuous service.

Industry Context

NA

Related Party Transactions

• Indirect beneficial ownership of 1,554,586 Ordinary Shares through The Yoon Family Trust, dated December 11, 2019, where Jun Sik Yoon and Hayung Yang Yoon are Trustees.

Stakeholder Impact

• Shareholders: Provides transparency on insider holdings and compensation, indicating management's vested interest in the company's performance. The vesting of PSUs suggests the company is meeting internal performance targets, which could be viewed positively.
• Employees: Reflects the company's equity compensation structure and how performance-based awards vest.

Next Steps

• The remaining 50% of the performance-vesting restricted share units (PSUs) are scheduled to vest on January 1, 2027, subject to the reporting person's continuous service.

Key Dates

Recommendation

Keywords

Structure Therapeutics, GPCR, SEC Form 4, Insider Trading, Share Ownership, Restricted Share Units, Performance Share Units, CFO, Jun Yoon, Equity Compensation, ADS, American Depositary Shares